SCHEMBL2930679

SCHEMBL2930679

[CH2]CNCC(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diisopropanolamine SCHEMBL22774 0.81
Diisopropanolamine SCHEMBL10618901 0.81
Diisopropanolamine SCHEMBL7592152 0.78 TSHR (0.41)
Diisopropanolamine SCHEMBL3362609 0.78 ALDH1A1 (0.43)
Diisopropanolamine SCHEMBL6858463 0.78 TSHR (0.41)
Diisopropanolamine SCHEMBL28590399 0.78 TSHR (0.41)
Diisopropanolamine SCHEMBL839563 0.78 TSHR (0.41)
SCHEMBL727619 0.75 KMT2A (0.47)
SCHEMBL367291 0.75
SCHEMBL11501652 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107973788-B BBI608 derivative and preparation and application thereof 沈阳药科大学 2021-07-09 CN claimed
US-20060147498-A1 Composition material for transmucosal delivery MAGLE HOLDING AB (SE) 2006-07-06 US claimed
US-20060074105-A1 Substituted quinoline and quinazoline inhibitors of quinone reductase 2 SERENEX, INC. (US) 2006-04-06 US claimed
WO-2006034235-A2 SUBSTITUTED QUINOLINE AND QUINAZOLINE INHIBITORS OF QUINONE REDUCTASE 2 SERENEX, INC. (US) 2006-03-30 WO claimed
US-4650909-A PURIFICATION BY ION EXCHANGE YOAKUM GEORGE H 1987-03-17 US claimed
EP-0077826-A4 AGENTS FOR ARRESTING FULMINATING INFECTION. EVREKA INC (US) 1984-01-16 EP claimed
EP-0077826-A1 AGENTS FOR ARRESTING FULMINATING INFECTION. EVREKA INC (US) 1983-05-04 EP claimed
WO-1982003770-A1 METHOD AND AGENTS FOR ARRESTING FULMINATING INFECTION EVREKA INC (US) 1982-11-11 WO claimed
US-4286067-A Article of manufacture comprising semipermeable polymer and dextran derivative ALZA CORPORATION (US) 1981-08-25 US claimed
CN-107973788-B BBI608 derivative and preparation and application thereof 沈阳药科大学 2021-07-09 CN disclosed
CN-112996789-A Antiviral pyridopyrazinedione compounds 诺华股份有限公司 2021-06-18 CN disclosed
US-9752192-B2 Compositions and methods for diagnosing autism RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-09-05 US disclosed
US-20130183669-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING AUTISM RUTGERS, THE STATE UNIVERSITY (US) 2013-07-18 US disclosed
US-20100330113-A1 Vaccine Antigens INTERVET INTERNATIONAL B.V. 2010-12-30 US disclosed
US-20030082173-A1 Lymphocyte surface receptor that binds CAML and methods of use thereof ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. 2003-05-01 US disclosed
US-20020197690-A1 GNK interacting amino acid decarboxylase and methods of use thereof IMMUNEX CORPORATION 2002-12-26 US disclosed
EP-0362283-A4 BOVINE INTERLEUKIN-1_G(A) 1991-10-16 EP disclosed
EP-0362283-A1 BOVINE INTERLEUKIN-1 ALPHA. IMMUNEX CORP (US) 1990-04-11 EP disclosed
WO-1988009382-A1 BOVINE INTERLEUKIN-1alpha IMMUNEX CORPORATION (US) 1988-12-01 WO disclosed
EP-0289129-A2 High purity protein A preparation REPLIGEN CORPORATION (US) 1988-11-02 EP disclosed